腹膜癌-话题@MedSci

#腹膜癌#

24篇内容 | 1223人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2186032, encodeId=ddc4218603233, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=简化腹膜癌指数（SPCI）, objectType=article, longId=812445, objectId=8e5a81244588, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016537876_4754896.png, objectUrl=/article/show_article.do?id=8e5a81244588, replyNumber=0, likeNumber=9, createdTime=2024-02-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8e5a81244588, moduleTitle=简化腹膜癌指数（SPCI）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e5a81244588)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2185389, encodeId=1fb32185389a7, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=新更公式：腹膜癌指数（PCI）计算, objectType=article, longId=811921, objectId=6ef6811921f0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679868291138_4754896.png, objectUrl=/article/show_article.do?id=6ef6811921f0, replyNumber=0, likeNumber=9, createdTime=2024-02-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6ef6811921f0, moduleTitle=新更公式：腹膜癌指数（PCI）计算, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ef6811921f0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1280102, encodeId=0eba1280102b5, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=J Clin Oncol：降风险的输卵管-卵巢切除术（RRSO），能否降低原发性腹膜癌的风险？, objectType=article, longId=724860, objectId=9fa0e24860ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fa0e24860ae, replyNumber=0, likeNumber=39, createdTime=2022-04-25, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fa0e24860ae, moduleTitle=J Clin Oncol：降风险的输卵管-卵巢切除术（RRSO），能否降低原发性腹膜癌的风险？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fa0e24860ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280101, encodeId=745112801013b, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, objectType=article, longId=301442, objectId=1e71301442a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e71301442a7, replyNumber=0, likeNumber=34, createdTime=2022-03-24, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e71301442a7, moduleTitle=J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e71301442a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280100, encodeId=16dc1280100e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌, objectType=article, longId=293566, objectId=93972935663a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93972935663a, replyNumber=0, likeNumber=42, createdTime=2022-01-09, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93972935663a, moduleTitle=Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93972935663a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280099, encodeId=63b612800995b, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果, objectType=article, longId=221499, objectId=28ce221499a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28ce221499a5, replyNumber=0, likeNumber=44, createdTime=2021-12-05, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28ce221499a5, moduleTitle=Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28ce221499a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280098, encodeId=5e10128009830, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, objectType=article, longId=217313, objectId=046121e3130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046121e3130e, replyNumber=0, likeNumber=39, createdTime=2021-09-20, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046121e3130e, moduleTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=046121e3130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280097, encodeId=dd16128009e67, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率, objectType=article, longId=205053, objectId=bd212050532b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd212050532b, replyNumber=0, likeNumber=38, createdTime=2021-01-01, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd212050532b, moduleTitle=Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd212050532b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280096, encodeId=28531280096e2, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, objectType=article, longId=197631, objectId=9f1c19e631bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f1c19e631bf, replyNumber=0, likeNumber=42, createdTime=2020-07-18, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f1c19e631bf, moduleTitle=三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f1c19e631bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280095, encodeId=035c128009586, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, objectType=article, longId=197253, objectId=32b119e253bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32b119e253bc, replyNumber=0, likeNumber=29, createdTime=2020-07-10, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32b119e253bc, moduleTitle=Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32b119e253bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280094, encodeId=80cc128009462, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究, objectType=article, longId=197252, objectId=947b19e25234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=947b19e25234, replyNumber=0, likeNumber=48, createdTime=2020-07-10, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=947b19e25234, moduleTitle=Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=947b19e25234)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280093, encodeId=3fe4128009311, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, objectType=article, longId=192309, objectId=fb70192309d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb70192309d8, replyNumber=0, likeNumber=36, createdTime=2020-04-16, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb70192309d8, moduleTitle=患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb70192309d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280092, encodeId=72d612800928b, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, objectType=article, longId=186454, objectId=6fbf186454dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fbf186454dd, replyNumber=0, likeNumber=49, createdTime=2020-01-19, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fbf186454dd, moduleTitle=英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fbf186454dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280091, encodeId=e6b71280091fd, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, objectType=article, longId=184088, objectId=1ff918408873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ff918408873, replyNumber=0, likeNumber=39, createdTime=2019-12-05, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ff918408873, moduleTitle=NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ff918408873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280090, encodeId=039712800906a, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V2）, objectType=article, longId=180067, objectId=df2118006efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2118006efe, replyNumber=0, likeNumber=21, createdTime=2019-09-27, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2118006efe, moduleTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2118006efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280089, encodeId=80341280089f5, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=Clinica Chimica Acta：对晚期上皮性卵巢癌或腹膜癌间隔减容手术疗效的多因素影响, objectType=article, longId=179571, objectId=e90f1e95717a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e90f1e95717a, replyNumber=0, likeNumber=27, createdTime=2019-09-18, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e90f1e95717a, moduleTitle=Clinica Chimica Acta：对晚期上皮性卵巢癌或腹膜癌间隔减容手术疗效的多因素影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e90f1e95717a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280088, encodeId=5185128008860, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V1）, objectType=article, longId=163060, objectId=4da1163060be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4da1163060be, replyNumber=0, likeNumber=0, createdTime=2019-03-28, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4da1163060be, moduleTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4da1163060be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280087, encodeId=094d128008ec4, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=2018 KSOG立场声明：双侧输卵管切除术降低平均风险女性卵巢癌/输卵管癌/腹膜癌风险, objectType=article, longId=150373, objectId=34251503e32a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34251503e32a, replyNumber=0, likeNumber=36, createdTime=2018-10-06, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34251503e32a, moduleTitle=2018 KSOG立场声明：双侧输卵管切除术降低平均风险女性卵巢癌/输卵管癌/腹膜癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34251503e32a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280086, encodeId=a22c1280086bb, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=《2018 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南》解读, objectType=article, longId=139292, objectId=f7881392924f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7881392924f, replyNumber=0, likeNumber=30, createdTime=2018-05-29, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7881392924f, moduleTitle=《2018 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南》解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7881392924f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1280085, encodeId=5c69128008581, content=<a href='/topic/show?id=94f28566004' target=_blank style='color:#2F92EE;'>#腹膜癌#</a>, objectTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2018.V2）, objectType=article, longId=132760, objectId=85da132e606b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85da132e606b, replyNumber=0, likeNumber=22, createdTime=2018-03-19, rootId=0, userName=3631173, userId=6f7a159, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85da132e606b, moduleTitle=NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2018.V2）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85da132e606b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

腹膜癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#腹膜癌#

简化腹膜癌指数（SPCI）

2024-02-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#腹膜癌#

新更公式：腹膜癌指数（PCI）计算

2024-02-02发表于上海

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

J Clin Oncol：降风险的输卵管-卵巢切除术（RRSO），能否降低原发性腹膜癌的风险？

2022-04-25

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

J clin oncol：BRCA1/2致病性变异携带者输卵管卵巢切除术后发生腹膜癌的风险

2022-03-24

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Clin Cancer Res：Adavosertib联合各种化疗药治疗原发铂耐药的卵巢癌、输卵管癌、腹膜癌

2022-01-09

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Clin Cancer Res：Adavosertib联合化疗治疗铂耐药的卵巢癌、输卵管癌及腹膜癌的效果

2021-12-05

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效

2021-09-20

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Lancet oncol：ICON8试验| 卵巢、输卵管、腹膜癌经卡铂-紫杉醇一线新辅助化疗后的客观缓解率

2021-01-01

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

三功能双特异性抗体Catumaxomab治疗腹膜癌，获得NMPA授权开始全球性3期临床试验

2020-07-18

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Gynecol Oncol：新诊断的卵巢癌、原发性腹膜癌和输卵管癌的静脉或腹膜内铂类化疗联合Veliparib和Bevacizumab的I期研究

2020-07-10

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Gynecol Oncol：依维莫司和贝伐单抗在复发性卵巢癌，腹膜癌和输卵管癌中的II期研究

2020-07-10

hb2008ye (审核中...)

前往app查看评论内容

#腹膜癌#

患者招募：评价SCB-313用于治疗腹膜癌患者的I期临床试验

2020-04-16

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

英国NICE批准将PARP抑制剂Lynparza，用于BRCA1或BRCA2突变的铂敏感型卵巢癌、输卵管癌或腹膜癌复发患者

2020-01-19

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

NICE批准PARP抑制剂Lynparza扩展用于晚期卵巢癌、输卵管癌和腹膜癌的维持治疗

2019-12-05

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V2）

2019-09-27

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

Clinica Chimica Acta：对晚期上皮性卵巢癌或腹膜癌间隔减容手术疗效的多因素影响

2019-09-18

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2019.V1）

2019-03-28

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

2018 KSOG立场声明：双侧输卵管切除术降低平均风险女性卵巢癌/输卵管癌/腹膜癌风险

2018-10-06

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

《2018 NCCN卵巢癌包括输卵管癌及原发性腹膜癌临床实践指南》解读

2018-05-29

3631173 (审核中...)

前往app查看评论内容

#腹膜癌#

NCCN临床实践指南：卵巢癌包括输卵管癌和原发性腹膜癌（2018.V2）

2018-03-19

科室
- - 订阅+
  - 更多科室
工具
服务